Nosal' L A, Simonova N V, Dorovskikh V A, Shtarberg M A
Amur State Medical Academy, Blagoveshchensk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(11. Vyp. 2):74-79. doi: 10.17116/jnevro201911911274.
To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the antioxidant status.
The antioxidant activity of reamberin was investigated in children with epilepsy: 16 patients received intravenous reamberin once daily for 5 days in addition to carbamazepine. Patients of the control group (n=15) received only carbamazepine. The efficacy of the drug was evaluated by the levels of lipid hydroperoxides, conjugated dienes, and malondialdehyde and by the activity of the main components of the antioxidant system (ceruloplasmin, vitamin E, catalase) in the blood of patients.
Reamberin significantly reduces the plasma levels of lipid hydroperoxides by 16%, conjugated dienes by 12%, and malondialdehyde by 25% compared with the patients of the control group. An analysis of the effect of succinate-containing drugs on the activity of the antioxidant system components has shown that blood concentrations of ceruloplasmin, vitamin E and catalase are by 35, 14% and 15%, respectively, higher than those in the control group. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered pathogenetically justified, clinically reasonable, and promising.